Q4FY26: Pharma Majors Post a Mix Bag
The Indian pharmaceutical sector is witnessing a trend where companies are aggressively acquiring brands and expanding.
Freepik
Opinions expressed by Entrepreneur contributors are their own.
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
Recent Q4 FY26 results for major pharmaceutical companies show a mix of surging revenues, margin pressure, and strategic acquisitions. The Indian pharmaceutical sector is witnessing a trend where companies are aggressively acquiring brands and expanding.
Pharma major Sun Pharmaceutical Industries reported a 26.24 per cent year-on-year (YoY) rise in its consolidated profit to INR 2,714.03 crore for the January-March quarter of the financial year 2026 (Q4FY26). In the same quarter of the previous financial year, Sun Pharma clocked a profit of INR 2,149.88 crore. Total revenue from operations for the quarter under review rose 12.8 per cent YoY.
“Our full-year performance reflects several significant achievements. Sun’s 0.3 percentage point gain in the India market is our highest gain since the Ranbaxy acquisition. Our U.S. Innovative Medicines business has surpassed USD 1 billion in revenues, while Ex-US Innovative Medicines continues to demonstrate strong growth momentum. The recently announced Organon acquisition is expected to further accelerate Sun’s transformation into a leading global pharmaceutical company,” said Kirti Ganorkar, MD, Sun Pharma.
Formulation sales in the US were US$ 459 million, lower by 1.1 per cent. Innovative Medicines continued to grow offsetting the decline in generics business. US sales accounted for approximately 28.8 per cent of total consolidated sales. For the full year FY26, sales were US$ 1,904 million, noted a statement.
Divi’s Laboratories reported a 13.4 per cent YoY rise in net profit for the January-March quarter of FY26 at INR 751 crore. Revenue for the quarter rose 9.5 per cent from a year earlier to INR 2,831 crore. Earnings before interest, taxes, depreciation and amortisation (EBITDA) increased 5.4 per cent YoY to INR 934 crore.
Torrent Pharmaceuticals reported a 27 per cent decline in profit after tax to INR 364 crore in the fourth quarter ended March 31, 2026, impacted by exceptional items outgo. The company had posted a net profit of INR 498 crore in the corresponding period of the previous fiscal, company said in a statement.
Total revenue from operations in the fourth quarter of FY26 stood at INR 4,197 crore as against INR 2,959 crore in the year-ago period, it added.
The pharma company’s India business revenue stood at INR 2,215 crore, up 43 per cent, in the quarter, while the Brazil revenue stood at INR 455 crore, up by 30 per cent. Revenue from the US business stood at INR 396 crore, up 31 per cent YoY, Torrent Pharma noted.
Torrent Pharmaceuticals has officially taken a controlling stake in JB Chemicals and Pharmaceuticals (JB Pharma) in a landmark deal valued at INR 25,689 crore. The acquisition was completed on January 21, 2026, and ranks as one of the largest merger and acquisition transactions in the history of the Indian pharmaceutical industry.
Drug maker Aurobindo Pharma reported a two per cent YoY increase in consolidated net profit to INR 921 crore for the March quarter, compared with INR 903 crore in the corresponding quarter last year.
Vice-chairman and managing director K. Nithyananda Reddy said, “We are encouraged by our performance for the quarter and the year, reflecting the resilience of our business model and the strength of our extensive product portfolio. Consistent volumes coupled with improved operating efficiencies and disciplined execution have contributed positively to our results.”
For FY26, the net profit was flat at INR 3,503 crore on a 6.1 per cent increase in revenue from operations to INR 33,653 crore (INR 31,724 crore). The company said its European business crossed €1 billion in revenues during the fiscal.
Recent Q4 FY26 results for major pharmaceutical companies show a mix of surging revenues, margin pressure, and strategic acquisitions. The Indian pharmaceutical sector is witnessing a trend where companies are aggressively acquiring brands and expanding.
Pharma major Sun Pharmaceutical Industries reported a 26.24 per cent year-on-year (YoY) rise in its consolidated profit to INR 2,714.03 crore for the January-March quarter of the financial year 2026 (Q4FY26). In the same quarter of the previous financial year, Sun Pharma clocked a profit of INR 2,149.88 crore. Total revenue from operations for the quarter under review rose 12.8 per cent YoY.
“Our full-year performance reflects several significant achievements. Sun’s 0.3 percentage point gain in the India market is our highest gain since the Ranbaxy acquisition. Our U.S. Innovative Medicines business has surpassed USD 1 billion in revenues, while Ex-US Innovative Medicines continues to demonstrate strong growth momentum. The recently announced Organon acquisition is expected to further accelerate Sun’s transformation into a leading global pharmaceutical company,” said Kirti Ganorkar, MD, Sun Pharma.
